Inventor · disambiguated record
Hubert Metzner
Also filed as: METZNER HUBERT · METZNER HUBERT J
28 granted patents·15 pending applications·381 citations·filing 1997–2020
96Inventor score
Top patents by PatentIndex Score
43 records- 0197US7939632B2Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2007·Granted May 10, 2011·40 cites·31 claims
- 0292US9956269B2Method for improving the stability of purified factor VIII after reconstitutionCSL LTD·Filed 2016·Granted May 1, 2018·12 cites·18 claims
- 0390US7045601B2Storage-stable, liquid fibrinogen formulationZLB BEHRING GMBH·Filed 2003·Granted May 16, 2006·53 cites·34 claims
- 0489US10881717B2Method for improving the stability of purified Factor VIII after reconstitutionCSL LTD·Filed 2019·Granted Jan 5, 2021·3 cites·24 claims
- 0589US8754194B2Modified coagulation factors with prolonged in vivo half-lifeSCHULTE STEFAN·Filed 2007·Granted Jun 17, 2014·12 cites·15 claims
- 0688US9878017B2Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating theretoCSL LTD·Filed 2014·Granted Jan 30, 2018·4 cites·20 claims
- 0788US8575104B2Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-lifeWEIMER THOMAS·Filed 2009·Granted Nov 5, 2013·18 cites·27 claims
- 0888US7550567B2Fibrinogen purificationCSL BEHRING GMBH·Filed 2005·Granted Jun 23, 2009·21 cites·21 claims
- 0988US7351561B2Thrombin preparations and process for their productionCSL BEHRING GMBH·Filed 2001·Granted Apr 1, 2008·28 cites·6 claims
- 1087US10537616B2Method for improving the stability of purified factor VIII after reconstitutionCSL LTD·Filed 2018·Granted Jan 21, 2020·5 cites·18 claims
- 1187US9394353B2Method for improving the stability of purified factor VIII after reconstitutionCSL LTD·Filed 2012·Granted Jul 19, 2016·9 cites·7 claims
- 1284US10688157B2Truncated von Willebrand factor polypeptides for treating hemophiliaCSL Behring Lengnau AG·Filed 2016·Granted Jun 23, 2020·2 cites·23 claims
- 1376US8012728B2Thrombin preparations and process for their productionCSL BEHRING GMBH·Filed 2006·Granted Sep 6, 2011·2 cites·10 claims
- 1476US7276235B2Tissue glue with improved antiadhesive propertiesZLB BEHRING GMBH·Filed 2002·Granted Oct 2, 2007·33 cites·30 claims
- 1575US7939288B2Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniquesCSL BEHRING GMBH·Filed 2006·Granted May 10, 2011·7 cites·34 claims
- 1674US11510968B2Method for improving the stability of purified Factor VIII after reconstitutionCSL LTD·Filed 2020·Granted Nov 29, 2022·0 cites·24 claims
- 1769US6790410B2Use of a hydrogen peroxide plasma sterilization method for the mild sterilization of temperature-sensitive productsAVENTIS BEHRING GMBH·Filed 2002·Granted Sep 14, 2004·17 cites·25 claims
- 1868US9290561B2Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-lifeWEIMER THOMAS·Filed 2013·Granted Mar 22, 2016·1 cites·31 claims
- 1968US6874657B2Biological sealant storage and dispensing systemZLB BEHRING GMBH·Filed 2002·Granted Apr 5, 2005·56 cites·39 claims
- 2068US6204036B1Stable transglutaminase preparations and processes for their productionAVENTIS BEHRING GMBH·Filed 1997·Granted Mar 20, 2001·26 cites·37 claims
- 2167US2020095567A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2019·Application pending·0 cites
- 2267US2018119128A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2017·Application pending·0 cites
- 2359US2011189182A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2011·Application pending·0 cites
- 2459US2016010074A1Proteolytically cleavable fusion proteins with high molar specific activityCSL BEHRING GMBH·Filed 2015·Application pending·0 cites
- 2558US11554156B2Pharmaceutical formulations of C1 esterase inhibitorCSL BEHRING GMBH·Filed 2020·Granted Jan 17, 2023·0 cites·16 claims
- 2657US2014248686A1Therapeutic polypeptides with increased in vivo recoveryCSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 2756US2010222554A1Method of Increasing the In Vivo Recovery of Therapeutic PolypeptidesWEIMER THOMAS·Filed 2007·Application pending·0 cites
- 2855US11479578B2Protein purification and virus inactivation with alkyl glycosidesCSL Behring Lengnau AG·Filed 2018·Granted Oct 25, 2022·0 cites·33 claims
- 2954US2013337532A1Therapeutic polypeptides with increased in vivo recoveryWEIMER THOMAS·Filed 2013·Application pending·0 cites
- 3054US2018092966A1Covalent complex of von willebrand factor and factor viii, compositions, and uses relating theretoCSL LTD·Filed 2017·Application pending·0 cites
- 3153US2014273096A1Modified coagulation factors with prolonged in vivo half-lifeCSL BEHRING GMBH·Filed 2014·Application pending·0 cites
- 3252US9511123B2Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIIICSL BEHRING GMBH·Filed 2012·Granted Dec 6, 2016·0 cites·5 claims
- 3351US2022389082A1A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viiiCSL Behring Lengnau AG·Filed 2020·Application pending·0 cites
- 3450US6447774B1Stabilized protein preparations for a tissue adhesiveAVENTIS BEHRING GMBH·Filed 1999·Granted Sep 10, 2002·31 cites·20 claims
- 3549US9393289B2Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIIICSL BEHRING GMBH·Filed 2012·Granted Jul 19, 2016·0 cites·18 claims
- 3648US2019175683A1Pharmaceutical formulations of c1 esterase inhibitorCSL BEHRING GMBH·Filed 2017·Application pending·0 cites
- 3747US2009042787A1Proteolytically cleavable fusion proteins with high molar specific activityMETZNER HUBERT·Filed 2007·Application pending·0 cites
- 3843US11814421B2Truncated von Willebrand Factor polypeptides for treating hemophiliaCSL Behring Lengnau AG·Filed 2017·Granted Nov 14, 2023·0 cites·24 claims
- 3940US2002001584A1Tissue glue with improved antiadhesive propertiesAVENTIS BEHRING GMBH·Filed 2001·Application pending·0 cites
- 4034US2017209546A1Improved factor viii preparations suitable for therapeutic use and processes to obtain theseCSL BEHRING GMBH·Filed 2015·Application pending·0 cites
- 4130US10238718B2Factor VIII formulationCSL LTD·Filed 2015·Granted Mar 26, 2019·0 cites·24 claims
- 4229US6207877B1Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleedingAVENTIS BEHRING GMBH·Filed 1999·Granted Mar 27, 2001·1 cites·7 claims
- 4329US2018036394A1Pharmaceutical formulations of c1 esterase inhibitorCSL BEHRING GMBH·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →